Blog
Switching From Tirzepatide to Retatrutide: What Dose to Start On and When
Most people looking up how to switch from tirzepatide to retatrutide have been on tirzepatide for months. Some have stalled at 10 or 15mg. Others want the extra ground retatrutide covered in its trials, where 12mg a week took off 28.3% of body weight on average by week 80 in TRIUMPH-1. Either way the questions are the same two: which retatrutide dose comes first, and on which day.
The trials can’t answer either one directly. Every Phase 3 retatrutide trial turned away anyone who had used a weight-loss drug in the 90 days before screening, so not one participant went straight from tirzepatide to retatrutide. The advice that fills the gap runs from a flat 2mg, to a quarter of the old tirzepatide milligrams, to a month-long taper and a two-week break before a tiny first dose.
What does exist is enough to plan on: retatrutide tested at two starting doses, two half-lives that overlap neatly, and years of switches between other weekly incretin drugs. For laboratory research, Simms Research sells Retatrutide (GLP-3) as freeze-dried powder in 10, 20, 30 and 60mg vials, with its latest batch certificate posted.
Tirzepatide to retatrutide conversion
There is no milligram conversion. Each peptide got its own dose ladder from its own trials, so 15mg on one ladder says nothing about the other: it isn’t 12mg of retatrutide, and 2mg of retatrutide isn’t a smaller version of 2.5mg of tirzepatide. The thing that lines up is the result, meaning how much weight each dose took off in its main trial. Find the tirzepatide dose in the first column:
| Tirzepatide dose | Weight loss, SURMOUNT-1 (72 weeks) | Closest retatrutide match | Reached from a 2mg start |
|---|---|---|---|
| 2.5mg | Starting step, not kept | 2mg, also a starting step | Week 1 |
| 5mg | 16.0% | 4mg (19.0% at 80 weeks) | Week 5 |
| 10mg | 21.4% | Between 4mg and 6mg | Weeks 5 to 9 |
| 15mg | 22.5% | 6mg, the step between 4 and 9mg | Week 9 |
7.5mg and 12.5mg are passing steps with no result of their own; read them with the row below. The retatrutide figures come from TRIUMPH-1, where 4mg produced 19.0% and 9mg 25.9%, and both trials counted people while they stayed on treatment. Treat each match as a neighborhood, not an exact swap: SURMOUNT-1 ran 72 weeks and TRIUMPH-1 ran 80, in different people.
The last column is the one that shapes the switch. Someone coming off 5mg is back at a comparable strength one month after the first retatrutide shot. Someone coming off 10 or 15mg, starting at 2mg, spends roughly two months below where tirzepatide had them. How to handle that gap is the whole starting-dose question.
Switching from tirzepatide to retatrutide: starting dose
2mg for most people, and 4mg for some coming off a high tirzepatide dose. No retatrutide trial has opened a weekly course above 4mg, so the ceiling for a first shot is 4mg whatever the tirzepatide dose was.
The Phase 2 obesity trial ran those two starts side by side. Among people heading to 8mg, nausea hit 60% of the group that started at 4mg and 17% of the group that started at 2mg, against 11% on placebo; vomiting ran 26% against 6%. Among people heading to 4mg, nausea was 36% with the 4mg start and 18% with the 2mg start. The faster start did buy some weight: at 48 weeks the 4mg starters were ahead by 1.5 points in the 4mg groups (17.8% against 16.3%) and by 2.2 points in the 8mg groups (23.9% against 21.7%) (Jastreboff et al., NEJM, 2023). That trade is why every Phase 3 trial opened at 2mg.
Those participants had never taken an incretin drug, though, and a switcher arrives after months of GLP-1 and GIP signaling. Switching guidance for GLP-1 drugs splits on tolerance: people comfortable on their current drug can start the new one near an effective dose, while anyone switching because of nausea or vomiting waits for it to settle and starts at the bottom (Almandoz et al., Clinical Diabetes, 2020). A November 2026 expert consensus on semaglutide-to-tirzepatide switches went further, warning that a mandatory lowest-dose restart risks a treatment gap and regain (Schwartzberg et al., Expert Opinion on Pharmacotherapy, 2026).
Lilly is now testing the higher start itself: a Phase 2 trial begun in February 2026 gives about 300 adults 4mg from week one with no escalation, next to 2mg-to-4mg and 4mg-to-8mg arms, and finishes its main comparison in March 2027.
Switching from 2.5mg or 5mg tirzepatide
Start at 2mg. The 4mg step arrives in week 5 anyway, and 4mg of retatrutide already sits past what 5mg of tirzepatide produced. Starting higher saves a few weeks at the cost of side effects that doubled in Phase 2.
Switching from 7.5mg or 10mg tirzepatide
2mg is still the usual start. The gap is short: retatrutide reaches 4mg in week 5 and 6mg in week 9, and 10mg of tirzepatide sits only a little above the 4mg result. A 4mg start fits someone who has held 10mg for months with no stomach trouble.
Switching from 12.5mg or 15mg tirzepatide
This is where 4mg comes into play. From a 2mg start, someone leaving 15mg spends eight weeks at doses below their old result; from a 4mg start, about four. That route suits people who used 15mg without nausea. Anyone leaving tirzepatide because its side effects wore them down starts at 2mg, the way the switching guidance above sets it.

Tirzepatide to retatrutide transition: when to take the first dose
On your regular injection day, one week after the last tirzepatide shot. The first retatrutide shot takes the place of the next tirzepatide one, on the same weekday, with nothing in between.
Tirzepatide’s half-life of about five days sets the pace. On switch day it sits at its usual pre-shot low, the same point it reached every week. Without another shot it falls to roughly 38% of that low a week later, about 14% after two weeks and about 5% after three. Retatrutide climbs over the same month, so the two curves cross instead of leaving a hole. How retatrutide’s own level builds is in Retatrutide Half-Life.
Both alternatives cost something. Taking the two on the same day doubles up on the same receptors, since both peptides act on GLP-1 and GIP, and Zepbound’s label advises against combining tirzepatide with any GLP-1 drug. A break of two weeks or more does the opposite: tirzepatide drops to a sliver of its usual level before retatrutide has started building, and appetite comes back with nothing to meet it. A multi-week tirzepatide taper has no basis in any switching guidance and only stretches that low stretch out.
The one exception is a switch made because of side effects. If tirzepatide is causing nausea or vomiting, skip the overlap: wait until the symptoms settle, then start retatrutide at 2mg.
Can you take retatrutide and tirzepatide together?
No trial has combined them, and nothing about their design invites it. Retatrutide already carries tirzepatide’s two signals, GLP-1 and GIP, and adds glucagon as the third. Stacking the two would add more of what the stomach is already adjusting to, without a new mechanism. What each of the three receptors does is laid out in What Is Retatrutide? How the Reta Peptide Works.
Switching from tirzepatide to retatrutide dosage, week by week
Weeks 1 to 4 at 2mg, weeks 5 to 8 at 4mg, weeks 9 to 12 at 6mg, weeks 13 to 16 at 9mg, and 12mg from week 17 only if more is wanted. That is the TRIUMPH ladder, counted from the first retatrutide shot. A 4mg start skips the first rung and runs every later step four weeks sooner.
Four weeks is the shortest a step should last, not a timetable. The blood level keeps rising for the first few weeks of each step, so weeks two and three say more about a dose than week one, and holding a step longer while the stomach adjusts is normal.
The top of the ladder is a choice. Someone who came from 5mg of tirzepatide is already past their old result at 4mg of retatrutide, and nothing says to keep climbing once the scale is moving again. In TRIUMPH-1 the last 3mg bought 2.4 more points of weight loss and lifted the share stopping for side effects from 6.9% to 11.3%.
At 10mg per mL, a 10mg vial mixed with 1mL of water, 2mg is 20 units, 4mg is 40, 6mg is 60 and 9mg is 90. The retatrutide dosage chart covers other mixes and the 12mg dose, and the retatrutide calculator handles any vial and water volume.
The first two months take a 10mg vial for the 2mg step and a 20mg vial for the 4mg step, each with a dose spare. From a 4mg start, a 20mg vial covers the first month and a 30mg vial the 6mg month. Later months are priced dose by dose in Retatrutide Cost per Month.

Switching from tirzepatide to retatrutide side effects and the first month
Expect some appetite to come back in weeks 2 to 4, mild stomach effects around each new step, and a scale that moves slowly for the first month or two.
Appetite moves first. By the second week tirzepatide is down to around a seventh of its usual low while 2mg of retatrutide is still building. Hunger and food noise rising in that window is expected, most of all coming from 10 or 15mg, and it eases as the 4mg and 6mg steps arrive.
The stomach effects are the familiar ones: nausea, diarrhea, constipation and vomiting, the same family tirzepatide causes. In the Phase 2 trial they came mostly while the dose was climbing and were mostly mild to moderate. One effect is new. Retatrutide adds dysesthesia, a tingling or oversensitive feeling in the skin that tirzepatide doesn’t cause; in TRIUMPH-1 it affected 5.1% of people on 4mg against 0.9% on placebo, and it grows with dose. Rates for every dose are in Retatrutide Side Effects by Dose.
For the scale, the closest real-world data come from people who switched from semaglutide to tirzepatide. Those who switched at a plateau lost a further 8.1% over six months; those who switched because semaglutide had never worked for them lost 2.9%. People who had already lost 10% or more before starting tirzepatide lost less on it, 7.2% against 10.3% (Barenbaum et al., Obesity, 2026). A switch from tirzepatide starts from the same place, so expect a flatter curve than the trials show for people starting fresh. Why tirzepatide slows down in the first place is covered under tirzepatide plateau.
TRIUMPH-5, the 80-week head-to-head of retatrutide and tirzepatide in about 800 adults, had not reported by mid-November 2026, and it enrolled people new to both drugs, so it won’t show how a switch goes either. Retatrutide vs Tirzepatide: Which Is Better, Dose for Dose? sets the two side by side.
Switching from Mounjaro or Zepbound to retatrutide
The same way as from any tirzepatide, because Mounjaro and Zepbound are tirzepatide: find the dose on the pen in the conversion table and the starting-dose notes above. 5mg of Mounjaro starts retatrutide at 2mg, and 15mg of Mounjaro or Zepbound is where a 4mg start comes into play. The first retatrutide shot goes in on the day the next pen was due.
What changes is the handling. Zepbound and Mounjaro come as single-dose pens, and Zepbound also as single-dose vials, each a fixed weekly dose with nothing to measure. Research retatrutide is freeze-dried powder, mixed with bacteriostatic water and drawn in units on an insulin syringe. Simms Research sells bacteriostatic water as Research Water in 10mL vials; How to Reconstitute Retatrutide walks through the mixing for every vial size, and How to Inject Retatrutide covers the shot itself. For a dial-a-dose pen instead of a syringe, Retatrutide Pen shows how to fill a cartridge from the mixed vial.
A pen from the pharmacy holds its labeled dose. A research vial holds what its certificate says it holds, so the certificate is worth reading before the first draw. The latest Simms Research retatrutide batch measured 10.68mg in a 10mg vial, about 7% over the label, averaged across three vials.

Switching from tirzepatide to retatrutide for maintenance
It can be done, but it trades a tested maintenance plan for an untested one. Tirzepatide’s maintenance data are strong: in SURMOUNT-MAINTAIN, people who dropped from 10 or 15mg to 5mg held most of their loss for a year, and the tirzepatide dosage chart has the full numbers. Retatrutide’s version is still running. TRIUMPH-6 gives about 640 adults retatrutide for 80 weeks, then splits them between staying on their dose, changing dose or moving to placebo for 36 more weeks, with its main results due in 2028.
A common reason to switch at goal weight is weight creeping back on a low tirzepatide dose. That switch follows the same rules: 2mg on the next scheduled day, then up the ladder only as far as the scale needs. Retatrutide’s lower doses did real work in Phase 2, where 4mg produced 17.1% at 48 weeks, so holding weight seldom calls for the top of the ladder.
What dose to start on and when
Take the first retatrutide shot on the day the next tirzepatide shot was due, and skip that tirzepatide shot. Start at 2mg. Move to a 4mg start only if you are coming off 10mg or more of tirzepatide and have tolerated it without stomach trouble for months, and never higher than 4mg. Then climb in steps of at least four weeks, 4, 6, 9 and 12mg, stopping wherever the results and the side effects balance. Expect the first month to feel weaker than tirzepatide did, and judge the switch on the weeks after the 4mg and 6mg steps settle, not on the first two.
For laboratory research, Retatrutide (GLP-3) from Simms Research costs $84 for the 10mg vial, $129 for 20mg, $159 for 30mg and $259 for 60mg. The latest batch, tested July 16, 2026 by an independent ISO-certified lab, came back at 99.611% purity with identity confirmed by LC-MS, endotoxins passing, heavy metals negative and no microbial growth; the full report is under retatrutide lab results. Orders placed before 5PM Eastern ship from Florida the same day.
Frequently asked questions
Can you switch from retatrutide back to tirzepatide?
Yes, with the same rules in reverse: the first tirzepatide shot goes in on the day the next retatrutide shot was due, at 2.5mg, or at 5mg for someone who was comfortable on 4mg or more of retatrutide. Retatrutide fades a little more slowly than tirzepatide, so the overlap is gentle. Simms Research sells Tirzepatide (GLP-2) in 10 to 60mg vials, and Can You Stop Retatrutide Once You Start? covers what happens when retatrutide stops altogether.
Is switching from semaglutide to retatrutide the same?
The timing is the same: next scheduled day, no gap, with a slightly longer overlap because semaglutide’s half-life is about seven days. Start at 2mg; semaglutide 2.4mg took off less weight in its main trial than retatrutide 4mg did in TRIUMPH-1.
Is Simms Research legit?
The parts a buyer can check say yes. Simms Research posts its retatrutide certificate before anyone orders, ships from Florida the same business day on orders placed before 5PM Eastern, and covers lost, stolen and damaged parcels under its Free Delivery Guarantee. Support answers at 855-592-8507 and support@simmsresearch.com, Monday to Friday, 9AM to 5PM Eastern, and every compound they carry is in the shop.
Does this page have a discount code?
No. There is no discount code or affiliate link here, and every price quoted is the regular price.